Literature DB >> 23718298

Ramucirumab: a novel antiangiogenic agent.

Roopma Wadhwa1, Takashi Taketa, Kazuki Sudo, Mariela Blum-Murphy, Jaffer A Ajani.   

Abstract

Ramucirumab (IMC-1121B) is a fully humanized monoclonal antibody that binds to VEGFR2 and can inhibit angiogenesis, a quintessential mechanism for promoting tumor growth and metastasis. Several antiangiogenesis agents are already approved for cancer therapy; however, ramucirumab's selectivity for VEGFR2 makes it interesting. The selectivity of an agent can improve safety and efficacy. This article describes the mechanism of action, pharmacokinetics, safety and clinical trial results of ramucirumab with particular emphasis on gastric cancer.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23718298     DOI： 10.2217/fon.13.68

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  11 in total

Review 1.  Treatment options in patients with metastatic gastric cancer: current status and future perspectives.

Authors:  Ahmet Bilici
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

Review 2.  Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use.

Authors:  Giuseppe Aprile; Marta Bonotto; Elena Ongaro; Carmelo Pozzo; Francesco Giuliani
Journal:  Drugs       Date:  2013-12       Impact factor: 9.546

3.  Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer.

Authors:  Yan Zhu; Tiantian Tian; Zhongwu Li; Zhiyu Tang; Lai Wang; Jian Wu; Yilin Li; Bin Dong; Yanyan Li; Na Li; Jianling Zou; Jing Gao; Lin Shen
Journal:  Sci Rep       Date:  2015-02-25       Impact factor: 4.379

4.  Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors.

Authors:  Jaffer A Ajani; Jeannelyn S Estrella; Qiongrong Chen; Arlene M Correa; Lang Ma; Ailing W Scott; Jiankang Jin; Bin Liu; Min Xie; Kazuki Sudo; Hironori Shiozaki; Brian Badgwell; Brian Weston; Jeffrey H Lee; Manoop S Bhutani; Hisashi Onodera; Koyu Suzuki; Akihiro Suzuki; Sheng Ding; Wayne L Hofstetter; Randy L Johnson; Robert S Bresalier; Shumei Song
Journal:  Br J Cancer       Date:  2017-11-14       Impact factor: 7.640

Review 5.  Treatment outcome of anti-angiogenesis through VEGF-pathway in the management of gastric cancer: a systematic review of phase II and III clinical trials.

Authors:  Brian Mawalla; Xianglin Yuan; Xiaoxiao Luo; Phillip L Chalya
Journal:  BMC Res Notes       Date:  2018-01-12

Review 6.  Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity.

Authors:  Manuel Cobo; Vanesa Gutiérrez; Rosa Villatoro; Jose Manuel Trigo; Inmaculada Ramos; Omar López; María Ruiz; Ana Godoy; Irene López; Macarena Arroyo
Journal:  Lung Cancer (Auckl)       Date:  2017-07-12

Review 7.  Clinical utility of ramucirumab in advanced gastric cancer.

Authors:  Matthew Mk Chan; Katrin M Sjoquist; John R Zalcberg
Journal:  Biologics       Date:  2015-09-22

Review 8.  Ramucirumab: A New Therapy for Advanced Gastric Cancer.

Authors:  Andrea Landgraf Oholendt; Jennifer L Zadlo
Journal:  J Adv Pract Oncol       Date:  2015 Jan-Feb

Review 9.  Profile of ramucirumab in the treatment of metastatic non-small-cell lung cancer.

Authors:  Maryann R Cooper; Chelsea Binkowski; Jessica Hartung; Jennifer Towle
Journal:  Onco Targets Ther       Date:  2016-04-04       Impact factor: 4.147

10.  Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma.

Authors:  Robin L Jones; Daniela Katz; Elizabeth T Loggers; Darin Davidson; Eve T Rodler; Seth M Pollack
Journal:  Med Oncol       Date:  2017-08-29       Impact factor: 3.064
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.